11.12.07: Specialty Pharmaceuticals Report
4 analysts and top management from 1 firm examines specialty pharmaceuticals in this 26 page report from The Wall Street Transcript. Order this Report

  1. Outlook for Specialty Pharmaceuticals: David Lickrish, Broadpoint Capital, Inc.

  2. Brand Drug Marketers & Product Development Companies: Angela Larson, Susquehanna Financial Group

  3. Pain Management, Neuropathy & Dermatology: David H. Windley, Jefferies & Company, Inc.

  4. Drug Delivery & Specialty Pharma: Megan Murphy, Lazard Capital Markets

  5. CEO Interview (average 2,500 words): Top management from Synta Pharmaceuticals Corp. examines the outlook for their firm and sector.

    Topics covered include: Products ready to enter the clinic - Distribution - Secular changes - Incremental benefits of reformulations - New drug candidates - Innovative ideas - Patient demand - Profitable business models - Traditional medicinal chemistry Restructurings - Increased M&A activity - Clinical milestones - Market opportunity - Neurological disorders - Narcotic markets - Licensing activity - Intellectual property issues - Commercial infrastructure

    Companies mentioned include: DURECT (DRRX), Forest Labs (FRX), Anesiva (ANSV), Endo Pharmaceuticals (ENDP), POZEN (POZN), Forest Labs (FRX), Sciele (SCRX), DURECT (DRRX), Barrier Therapeutics (BTRX), Obagi Medical (OMPI), Sepracor (SEPR), King Pharmaceuticals (KG), Allergan (AGN), Shire (SHPGY), Alcon (ACL), Forest Laboratories (FRX), DURECT (DRRX), CollaGenex (CGPI), Cypress Bioscience (CYPB), NeurogesX (NGSX), Endo Pharmaceuticals (ENDP), Savient (SVNT), NeurogesX (NGSX), Forest Labs (FRX), and CollaGenex (CGPI).

    ORDER THIS REPORT NOW! CLICK HERE

 

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.


Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher

HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE